½ÃÀ庸°í¼­
»óǰÄÚµå
1541719

¼¼°èÀÇ ÇâÁø±ÕÁ¦ ½ÃÀå º¸°í¼­ : ¾àÁ¦ Ŭ·¡½ºº°, ÀûÀÀÁõº°, Áö¿ªº°(2024-2032³â)

Antifungal Drugs Market Report by Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, and Others), Indication (Dermatophytosis, Aspergillosis, Candidiasis, and Others), and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 147 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ç×Áø±ÕÁ¦ ½ÃÀå ±Ô¸ð´Â 2023³â 151¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ¿¹Ãø ±â°£ µ¿¾È 3.1%ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» º¸ÀÏ Àü¸ÁÀ̸ç 2032³â¿¡´Â 201¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

ÇâÁø±ÕÁ¦´Â ÇǺÎ, ¸ð¹ß ¹× ¼ÕÅéÀÇ °õÆÎÀÌ °¨¿°À» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀǾàǰÀ» ÀǹÌÇÕ´Ï´Ù. ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â Ç×Áø±ÕÁ¦·Î´Â Æú¸®¿£°è, ¾ÆÁ¹°è, ¾Ë¸±¾Æ¹Î°è µîÀÌ ÀÖ½À´Ï´Ù. À̵éÀº Ä­µð´Ù³ª ¹ú·¹ µîÀÇ Áø±ÕÀ̳ª ÇǺλç»ó±ÕÀ» ÁßÈ­ÇØ, ¹«Á», ¹é¼±, ¾Æ½ºÆä¸£±æ·ç½ºÁõ, Ä­µð´ÙÁõ, Áø±Õ¼º ¼ö¸·¿°ÀÇ Ä¡·á¸¦ µ½½À´Ï´Ù. ÀÌµé ¾àÁ¦´Â ½ÃÆÇ¾à(OTC)À¸·Î¼­ ĸ½¶Á¦, °ÖÁ¦, ¾×Á¦, Á¤Á¦ ¶Ç´Â Áø±Õ °¨¿°À» ÃÖ¼ÒÈ­ÇÏ°í ¿¹¹æÇϱâ À§ÇØ Ç÷·ù¿¡ Á÷Á¢ ÁÖÀÔÇÏ´Â Á¤¸Æ ÁÖ»ç¾×ÀÌ ÀϹÝÀûÀ¸·Î ÆÇ¸ÅµÇ°í ÀÖ½À´Ï´Ù.

Ç×Áø±ÕÁ¦ ½ÃÀå °æÇâ

°õÆÎÀÌ °¨¿°À̳ª ¿ø³» °¨¿°ÀÇ À¯ÇàÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ½ÃÀå ¼ºÀå¿¡ ¹àÀº Àü¸ÁÀ» °¡Á®¿À´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. Ç×Áø±ÕÁ¦´Â º´¿ø ³»ÀÇ ¿À¿°µÈ Ç¥¸é°ú ½Àµµ°¡ ³ôÀº ȯ°æ¿¡ ³ëÃâµÇ¾î ¹ß»ýÇÏ´Â Àü½Å¼º ¹× Ç¥À缺 °¨¿° ¸ðµÎ¿¡ È¿°úÀûÀÔ´Ï´Ù. °Ô´Ù°¡ µµ½Ã¿¡¼­µµ ³óÃÌ¿¡¼­µµ ½ÃÆÇ¾àÀ» ¼Õ½±°Ô ÀÔ¼öÇÒ ¼ö ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ´ëÁßÀÇ °Ç°­ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó °æ½Ã °¨¿°À» Àû½Ã¿¡ Ä¡·áÇϱâ À§ÇØ OTC Ä¡·á¸¦ ¼±ÅÃÇÏ´Â ¼ÒºñÀÚ°¡ ´Ã°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ä§½À¼º Áø±Õ °¨¿°ÀÇ Ä¡·á¿ë ÇÕ¼º°ú ¹ÝÇÕ¼º ¾ÆÁ¹°è È­ÇÕ¹°ÀÇ °³¹ß µî ´Ù¾çÇÑ Á¦Ç° Çõ½Åµµ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¦¾à Á¦Á¶¾÷ü´Â ½ºÇÁ·¹ÀÌ, Å©¸², Á¤Á¦, ÁÖ»çÁ¦ µî È¿´ÉÀ» ³ôÀÎ ½Å±Ô Ä¡·á ¿¬±¸ °³¹ß(R&D)¿¡µµ Àû±Ø ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. Á¦¾à ¾÷°èÀÇ ÇöÀúÇÑ ¼ºÀå, °øÁß º¸°ÇÀ» ÃËÁøÇÏ´Â Á¤ºÎÀÇ À¯¸®ÇÑ Á¤Ã¥ ÀÌÇà µî ±âŸ ¿äÀε鵵 ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • 2023³â ¼¼°èÀÇ Ç×Áø±ÕÁ¦ ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ¼¼°èÀÇ Ç×Áø±ÕÁ¦ ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°èÀÇ Ç×Áø±ÕÁ¦ ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâÀº?
  • ¼¼°èÀÇ Ç×Áø±ÕÁ¦ ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • Ç×Áø±ÕÁ¦ ½ÃÀåÀÇ ¾àǰ Ŭ·¡½ºº° ³»¿ªÀº?
  • Ç×Áø±ÕÁ¦ ½ÃÀåÀÇ ÀûÀÀÁõº° ³»¿ªÀº?
  • ¼¼°èÀÇ Ç×Áø±ÕÁ¦ ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°èÀÇ Ç×Áø±ÕÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ÁøÃâ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Ç×Áø±ÕÁ¦ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : ¾àÁ¦ Ŭ·¡½ºº°

  • ¾ÆÁ¹
    • ½ÃÀå µ¿Çâ
    • ÁÖ¿ä ºÎ¹®
      • º¸¸®ÄÚ³ªÁ¹(ºÎÀÌÆæµå)
      • Æ÷»çÄÚ³ªÁ¹(³ì»çÇÊ)
      • Ŭ·ÎÆ®¸®¸¶Á¹(Ä«³×½ºÅÙ)
      • ÀÌ»çºêÄÚ³ªÁ¹(Å©·¹¼¾¹Ù)
      • ±âŸ
    • ½ÃÀå ¿¹Ãø
  • ¿¡Å°³ë ĵµò
    • ½ÃÀå µ¿Çâ
    • ÁÖ¿ä ºÎ¹®
      • Ä«½ºÆ÷ȯ±ä(Ä­½Ã´Ù½º)
      • ¹ÌÄ«Æë±Ï(¹ÌÄ«¹Î/ÆÒ°¡µå)
      • ±âŸ
    • ½ÃÀå ¿¹Ãø
  • Æú¸®¿£
    • ½ÃÀå µ¿Çâ
    • ÁÖ¿ä ºÎ¹®
      • ¾ÏÈ£ÅÚ¸®½Å(¾Ïºñ¼Ø)
      • ±âŸ
    • ½ÃÀå ¿¹Ãø
  • ¾Ë¸±¾Æ¹Î
    • ½ÃÀå µ¿Çâ
    • ÁÖ¿ä ºÎ¹®
      • Å׸£ºñ³ªÇÉ(¶ó¹Ì¾Á)
      • ±âŸ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ

Á¦7Àå ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°

  • ÇǺλç»ó±ÕÁõ
  • ¾Æ½ºÆä¸£±æ·ç½ºÁõ
  • Ä­µð´ÙÁõ
    • ½ÃÀå µ¿Çâ
    • ÁÖ¿ä ºÎ¹®
      • ħ½À¼º Ä­µð´ÙÁõ
      • ¿ÜÀ½Áú Ä­µð´ÙÁõ(VVC)
      • ÀÔ, ¸ñ, ½Äµµ Ä­µð´ÙÁõ
      • ±âŸ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ

Á¦8Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦9Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Abbott Laboratories
    • Arcadia Consumer Healthcare Inc.
    • Astellas Pharma Inc.
    • Bayer AG
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Scynexis Inc.
BJH 24.09.20

The global antifungal drugs market size reached US$ 15.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 20.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.1% during 2024-2032.

Antifungal drugs, or antimycotic drugs, refer to the pharmaceutical medicines used for the treatment of fungal infections on skin, hair and nails. Some of the commonly used antifungal drugs include polyenes, azoles and allylamines. They specifically neutralize fungal agents and dermatophytes, such as candida and tapeworms, and aid in the treatment of athlete's foot, ringworm, aspergillosis, candidiasis and fungal meningitis. These drugs are commonly available in over the counter (OTC) capsule, gel, liquid and pill variants or intravenous solutions that are injected directly into the bloodstream to minimize and prevent fungal infection.

Antifungal Drugs Market Trends:

The increasing prevalence of fungal and nosocomial infections is one of the key factors creating a positive outlook for the market growth. Antifungal drugs are effective against both systemic and superficial infections that are acquired from exposure to contaminated surfaces in hospitals or humid conditions. Moreover, the convenient availability of OTC drugs in both urban and rural areas is providing a thrust to the market growth. With the rising health consciousness among the masses, consumers are increasingly opting for OTC therapeutics to timely treat minor infections. Additionally, various product innovations, such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections, are acting as other growth-inducing factors. Pharmaceutical manufacturers are also investing extensively in the research and development (R&D) of novel therapeutics in the form of sprays, creams, tablets and injections with enhanced efficacy. Other factors, including significant growth in the pharmaceutical industry, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antifungal drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class and indication.

Breakup by Drug Class:

Azoles

Voriconazole (Vfend)

Posaconazole (Noxafil)

Clotrimazole (Canesten)

Isavuconazole (CRESEMBA)

Others

Echinocandins

Caspofungin (Cancidas)

Micafungin (Mycamine/ Funguard)

Others

Polyenes

Amphotericin (AmBisome)

Others

Allylamines

Terbinafine (Lamisil)

Others

Others

Breakup by Indication:

Dermatophytosis

Aspergillosis

Candidiasis

Invasive Candidiasis

Vulvovaginal Candidiasis (VVC)

Mouth/Throat/Esophageal Candidiasis

Others

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arcadia Consumer Healthcare Inc., Astellas Pharma Inc., Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Scynexis Inc.

Key Questions Answered in This Report

  • 1. What was the size of the global antifungal drugs market in 2023?
  • 2. What is the expected growth rate of the global antifungal drugs market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global antifungal drugs market?
  • 4. What are the key factors driving the global antifungal drugs market?
  • 5. What is the breakup of the global antifungal drugs market based on the drug class?
  • 6. What is the breakup of the global antifungal drugs market based on the indication?
  • 7. What are the key regions in the global antifungal drugs market?
  • 8. Who are the key players/companies in the global antifungal drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antifungal Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Azoles
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Voriconazole (Vfend)
      • 6.1.2.2 Posaconazole (Noxafil)
      • 6.1.2.3 Clotrimazole (Canesten)
      • 6.1.2.4 Isavuconazole (CRESEMBA)
      • 6.1.2.5 Others
    • 6.1.3 Market Forecast
  • 6.2 Echinocandins
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Caspofungin (Cancidas)
      • 6.2.2.2 Micafungin (Mycamine/ Funguard)
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast
  • 6.3 Polyenes
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Amphotericin (AmBisome)
      • 6.3.2.2 Others
    • 6.3.3 Market Forecast
  • 6.4 Allylamines
    • 6.4.1 Market Trends
    • 6.4.2 Key Segments
      • 6.4.2.1 Terbinafine (Lamisil)
      • 6.4.2.2 Others
    • 6.4.3 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Dermatophytosis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Aspergillosis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Candidiasis
    • 7.3.1 Market Trends
    • 7.3.2 Key Segments
      • 7.3.2.1 Invasive Candidiasis
      • 7.3.2.2 Vulvovaginal Candidiasis (VVC)
      • 7.3.2.3 Mouth/Throat/Esophageal Candidiasis
      • 7.3.2.4 Others
    • 7.3.3 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbott Laboratories
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Arcadia Consumer Healthcare Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Astellas Pharma Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bayer AG
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 GlaxoSmithKline Plc
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 Merck & Co. Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Merck KGaA
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Novartis AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Pfizer Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Sanofi S.A.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Scynexis Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦